Stocks · News reference
OS Therapies (NYSE: OSTX) interim Phase 2b trial data shows a 71.2% 3-year overall survival rate for OST-HER2 vs. 45.8% for controls.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Overall survival data when compared with a combined published historical control arm being used for regulatory interactions. The analysis is from the Company's Phase 2b trial for the prevention or delay of
Filed: 2026-08-21 AccNo: 0001213900-26-092651 Size: 603 KB Item 1.01: Entry into a Material Definitive Agreement Item 9.01: Financial Statements and Exhibits
-SEC Filing